A cost-effectiveness analysis of sentinel lymph node biopsy compared with lymphadenectomy in intermediate- and high-risk endometrial carcinoma.

IF 4.1 2区 医学 Q1 OBSTETRICS & GYNECOLOGY
Pernille Bjerre Trent, Ane Gerda Eriksson, Anne Cathrine Staff, Knut Erling Juul-Hansen, Emily Annika Burger, Knut Reidar Wangen
{"title":"A cost-effectiveness analysis of sentinel lymph node biopsy compared with lymphadenectomy in intermediate- and high-risk endometrial carcinoma.","authors":"Pernille Bjerre Trent, Ane Gerda Eriksson, Anne Cathrine Staff, Knut Erling Juul-Hansen, Emily Annika Burger, Knut Reidar Wangen","doi":"10.1136/ijgc-2024-005906","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sentinel lymph node biopsy (SLN) is increasingly used for surgical staging of endometrial carcinoma.</p><p><strong>Objective: </strong>To estimate the effect and cost-effectiveness of the implementation of an SLN algorithm for surgical staging in patients with intermediate- and high-risk endometrial carcinoma compared with lymphadenectomy.</p><p><strong>Methods: </strong>We performed a model-based, cost-effectiveness analysis using primary data from a tertiary referral hospital that included 829 patients with endometrial carcinoma undergoing surgical staging. We quantified the health and economic outcomes from two time periods, before and after implementation of the SLN algorithm by robotic surgery. Costs were measured directly from the hospital's financial department, while long-term health outcomes were estimated using self-reported lymphedema and health-related quality-of-life among survivors. Sensitivity analyses were conducted to evaluate uncertainty.</p><p><strong>Results: </strong>We projected that the SLN implementation period, predominately reflecting use of robotic SLN, simultaneously improved health outcomes (0.08 incremental quality-adjusted life-years) and lowered costs (US$1051) compared with the prior period involving robotic or open lymphadenectomy. SLN remained more beneficial and less costly across key sensitivity analyses-namely, varying the cost of the robotic platform, surgical equipment, number of yearly robotic procedures, percentage of robotic procedures versus percentage of laparotomies, length of stay, and lymphedema development. After 1000 simulations of the model, SLN implementation provided greater health benefits for lower costs (ie, cost saving) in 89% of simulations.</p><p><strong>Conclusion: </strong>Implementation of an SLN algorithm in the staging of intermediate- and high-risk endometrial carcinoma improved health outcomes for lower costs compared with lymphadenectomy. Cost-effectiveness could further improve by continuing to increase the proportion of robotic procedures.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gynecological Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-005906","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Sentinel lymph node biopsy (SLN) is increasingly used for surgical staging of endometrial carcinoma.

Objective: To estimate the effect and cost-effectiveness of the implementation of an SLN algorithm for surgical staging in patients with intermediate- and high-risk endometrial carcinoma compared with lymphadenectomy.

Methods: We performed a model-based, cost-effectiveness analysis using primary data from a tertiary referral hospital that included 829 patients with endometrial carcinoma undergoing surgical staging. We quantified the health and economic outcomes from two time periods, before and after implementation of the SLN algorithm by robotic surgery. Costs were measured directly from the hospital's financial department, while long-term health outcomes were estimated using self-reported lymphedema and health-related quality-of-life among survivors. Sensitivity analyses were conducted to evaluate uncertainty.

Results: We projected that the SLN implementation period, predominately reflecting use of robotic SLN, simultaneously improved health outcomes (0.08 incremental quality-adjusted life-years) and lowered costs (US$1051) compared with the prior period involving robotic or open lymphadenectomy. SLN remained more beneficial and less costly across key sensitivity analyses-namely, varying the cost of the robotic platform, surgical equipment, number of yearly robotic procedures, percentage of robotic procedures versus percentage of laparotomies, length of stay, and lymphedema development. After 1000 simulations of the model, SLN implementation provided greater health benefits for lower costs (ie, cost saving) in 89% of simulations.

Conclusion: Implementation of an SLN algorithm in the staging of intermediate- and high-risk endometrial carcinoma improved health outcomes for lower costs compared with lymphadenectomy. Cost-effectiveness could further improve by continuing to increase the proportion of robotic procedures.

中高危子宫内膜癌前哨淋巴结活检与淋巴结切除术的成本效益分析。
背景:前哨淋巴结活检(SLN前哨淋巴结活检(SLN)越来越多地被用于子宫内膜癌的手术分期:与淋巴结切除术相比,估算在中高危子宫内膜癌患者手术分期中实施前哨淋巴结活检算法的效果和成本效益:我们利用一家三级转诊医院的原始数据进行了基于模型的成本效益分析,其中包括 829 名接受手术分期的子宫内膜癌患者。我们对机器人手术实施 SLN 算法前后两个时间段的健康和经济结果进行了量化。成本由医院财务部门直接测算,而长期健康结果则通过幸存者自我报告的淋巴水肿和与健康相关的生活质量进行估算。我们还进行了敏感性分析以评估不确定性:我们预测,与之前的机器人或开放式淋巴结切除术相比,SLN 实施期间(主要反映了机器人 SLN 的使用)同时改善了健康结果(0.08 个增量质量调整生命年)并降低了成本(1051 美元)。在关键的敏感性分析中,SLN 仍然更有益、成本更低,这些敏感性分析包括机器人平台的成本、手术设备、每年机器人手术的数量、机器人手术的百分比与开腹手术的百分比、住院时间和淋巴水肿的发展。在对模型进行 1000 次模拟后,在 89% 的模拟中,SLN 的实施以较低的成本带来了更大的健康效益(即节约成本):结论:与淋巴结切除术相比,在对中高危子宫内膜癌进行分期时采用 SLN 算法能以更低的成本改善医疗效果。通过继续增加机器人手术的比例,可进一步提高成本效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.60
自引率
10.40%
发文量
280
审稿时长
3-6 weeks
期刊介绍: The International Journal of Gynecological Cancer, the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research, reviews, and video articles. The audience consists of gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信